Dorota Pucyk, MD
Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1235275785
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,290 of the $14,996 with a category attached, or 82.0%. It is spread thinly across 42 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,708 and has fallen 97.9% since, to $79 in 2025.
Across 494 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Corcept Therapeutics$2K
- Lilly USA, LLC$1K
- Amgen$1K
- Sanofi-aventis U.S. LLC$1K
- AstraZeneca$1K
- plus $5K from 36 others
What the payments were for
- Consulting fees$1,62011%
- Speaking & faculty fees$8756%
- Food & beverage$12,29082%
- Education$2111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,996 in reported general payments places this provider in the 85th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $256,187 |
| MounjaroTirzepatide | 136 | $179,107 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 141 | $156,136 |
| JardianceEmpagliflozin | 101 | $131,952 |
| TrulicityDulaglutide | 45 | $88,202 |
| KerendiaFinerenone | 45 | $65,090 |
| FarxigaDapagliflozin Propanediol | 35 | $52,953 |
| RybelsusSemaglutide | 21 | $44,263 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $28,385 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $26,316 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $23,451 |
| JanuviaSitagliptin Phosphate | 16 | $21,751 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $21,583 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $20,666 |
| InvokanaCanagliflozin | 22 | $20,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,884 | $300,450185 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,384 | $273,300206 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,132 | $156,136141 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $327 | $153,535119 claims |
| BayerKerendia | $658 | $65,09045 claims |
| AstraZenecaFarxiga | $1,103 | $52,95335 claims |
| MerckJanuvia | $146 | $21,75116 claims |
| Johnson & JohnsonInvokana | $190 | $20,31422 claims |
| AbbVieSynthroid, Armour Thyroid | $258 | $13,270111 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $183 | $7,711369 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Tucson
- Muhammad SethiTucson$670K
- Karen HerbstTucson$200K
- Nora BarsonyTucson$121K
- Maria PosadasTucson$24K
- Neda EbrahimiTucson$11K
- Casey RendonTucson$9K
- Jonathan InselTucson$7K
- Roshanak HabibiTucson$7K
- Ramiro Cardenas LaraTucson$6K
- Cynthia Rivas PajueloTucson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.